12 Jun, 2020
Pantherna Therapeutics GmbH signs an agreement for technology evaluation with Astellas Innovation Management LLC to evaluate Pantherna’s lipid nanoparticle transport system and mRNA molecules.
Posted at 13:36h in Allgemein
Pantherna Therapeutics GmbH (“Pantherna”) announced today that it has signed an agreement for technology evaluation with Astellas Innovation Management LLC (Cambridge, Mass., USA), a subsidiary of Astellas Pharma Inc. Under the agreement the parties will investigate the efficiency and specificity of Pantherna’s lipid nanoparticle transport systems (PTXΔLNPs) to deliver Pantherna’s proprietary mRNA molecules (PTXmRNAs) by different routes of administration.back